First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

Back

ESC Premium Access

First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

Session: Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

Topic: Antidiabetic Pharmacotherapy

Speaker: Professor N. Marx (Aachen, DE)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)

46 presentations

10 followers

6 more presentations in this session

Circulating microparticules of patients with coronary artery disease up-regulate the expression of sodium-glucose cotransporters 1 and 2 in coronary artery endothelial cells: role of angiotensin II

Speaker: Doctor S. Park (Illkirch, FR)

Access

Abstract

Slides

Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.

Speaker: Doctor H. Kondo (Yufu City, JP)

Access

Abstract

Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials

Speaker: Doctor C. Parco (Duesseldorf, DE)

Access

Abstract

Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

Speaker: Mr J. Ghouse (Copenhagen, DK)

Access

Abstract

Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Speaker: Professor D. McGuire (Dallas, US)

Access

Abstract

Access the full session

Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

Speakers: Professor N. Marx, Doctor S. Park, Doctor H. Kondo, Doctor C. Parco, Mr J. Ghouse...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

About the speaker

Professor Nikolaus Marx

6 more presentations in this session

Circulating microparticules of patients with coronary artery disease up-regulate the expression of sodium-glucose cotransporters 1 and 2 in coronary artery endothelial cells: role of angiotensin II

Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.

Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials

Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Access the full session

Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

About the event

ESC Congress 2019

ESC 365 is supported by